Pilot study: The retina as a potential window to visualize neuropathology in Alzheimer's disease.

Pilot study: The retina as a potential window to visualize neuropathology in Alzheimer's disease. - Is Alzheimer's disease visible in the eye?

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42260

Enrollment

Registered

2014-12-08

Start date

2015-05-11

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Study cases: Patients with early onset (

Exclusion criteria

Exclusion criteria: - Patients with neuro-opthalmological conditions, which may interfere with the OCT and/or FAF data will be excluded (Table 2, Tewarie et al., 2012). - Patients with progressive dementia, with an MMSE below 17/30 and/or incapacitated and not capable to give informed consent - Patients with a narrow anterior angle of the eye and/or increased intra-ocular pressure. These patients have a contra-indication to use mydriatic agents.

Design outcomes

Primary

Measure	Time frame
Methods: We will conduct an overal examination of the eye, including vision, eye pressure and fundusphotography. With the use of FDT visual field examination and HRT scan of the optic disc, we aim to exclude glaucoma. Moreover, we conduct OCT and FAF measurements. Prior to measurements with OCT and FAF, pupil dilatation will be performed using tropicamide 0.5%. In total, the examinations will take around 45 minutes. Primary study parameters/outcome of the study: (1) Thickness of retina, macula and/or optic disc with OCT (2) Visualization of amyloid plaques in AD with FAF	—

Measure

Time frame

Methods: We will conduct an overal examination of the eye, including vision, eye pressure and fundusphotography. With the use of FDT visual field examination and HRT scan of the optic disc, we aim to exclude glaucoma. Moreover, we conduct OCT and FAF measurements. Prior to measurements with OCT and FAF, pupil dilatation will be performed using tropicamide 0.5%. In total, the examinations will take around 45 minutes. Primary study parameters/outcome of the study: (1) Thickness of retina, macula and/or optic disc with OCT (2) Visualization of amyloid plaques in AD with FAF

—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results